Sermorelin and tesamorelin are both growth-hormone-releasing-hormone (GHRH) analogs — they ask your own pituitary to release your own growth hormone, rather than supplying it from outside the body. They differ in potency, in how long they act, and in what the human evidence supports: tesamorelin is roughly forty times more potent and is the only one of the two with published visceral-fat trial data, while sermorelin is gentler and closer to the body’s own signaling. The question most people bring to this comparison is “which is stronger?” — but that is rarely the decision that matters. The better question is which one fits your physiology, your goal, and your baseline.
What follows is the honest comparison: the same job, two designs, and where each reasonably fits — without the certainty the category’s marketing usually claims.
The same job, two designs
Both peptides do the same fundamental thing. They bind GHRH receptors on the anterior pituitary and prompt it to make and release growth hormone on the body’s own terms. Neither one contains growth hormone. That is the defining difference between this class and injected recombinant growth hormone, which supplies the finished hormone directly and overrides the gland’s own regulation.
Where they part ways is structure. Sermorelin is a 29-amino-acid fragment — the working core of natural GHRH. Tesamorelin is a 44-amino-acid molecule with a trans-3-hexenoic acid group attached at one end, a modification that shields it from enzymatic breakdown and lengthens its effective action (Sermorelin vs Tesamorelin comparison, PlexusDx). Same signal; a sturdier, longer-lasting version of it.
Potency and half-life: what “stronger” actually means
Tesamorelin is approximately 40 times more potent than sermorelin, and it lasts meaningfully longer in the body. Sermorelin’s half-life is roughly 10–20 minutes; tesamorelin’s modification extends its half-life to roughly 26–38 minutes (PlexusDx).
It is worth being precise about what that does and does not mean. Higher potency and a longer half-life produce a stronger, more sustained stimulus to the growth-hormone axis. That is an advantage when the goal calls for it — and a reason for more careful dosing and monitoring, since a stronger stimulus also carries a higher rate of the class’s known effects, such as fluid retention and joint discomfort. “Stronger” is a design trade-off, not a verdict.
The evidence gap: visceral fat
This is where the two genuinely diverge on data, and it is the most important part of the comparison to state plainly.
Tesamorelin is FDA-approved — under the brand Egrifta — for the reduction of excess visceral abdominal fat in adults with HIV-associated lipodystrophy (FDA approval, FierceBiotech). In pooled Phase III trials of more than 800 participants, it selectively reduced visceral adipose tissue by about 15% over 26 weeks (and roughly 18% over 52 weeks), without meaningfully changing subcutaneous fat, limb fat, or overall body weight (Efficacy and safety of tesamorelin, PMC).
Sermorelin has no comparable visceral-fat trial. Its strongest human evidence sits in a different place entirely: diagnosing and treating growth-hormone deficiency, including in children — the use its former branded form, Geref, was approved for before it was discontinued in 2008 for commercial reasons.
Two honest cautions apply. First, tesamorelin’s visceral-fat data comes from a specific clinical population (people with HIV-associated lipodystrophy); its use for general body composition in healthy adults is off-label, and the trial figures should be read as evidence of mechanism, not a promise of the same result in a different person. Second, sermorelin’s lack of a visceral-fat trial is not evidence that it does nothing — it simply means the specific claim has not been tested to the same standard.
Sermorelin vs tesamorelin, compared
| Sermorelin | Tesamorelin | |
|---|---|---|
| Structure | 29-amino-acid GHRH analog | 44-amino-acid GHRH analog with a stabilizing modification |
| Relative potency | Baseline | ~40× more potent |
| Half-life | ~10–20 minutes | ~26–38 minutes |
| FDA-approval history | Approved as Geref for GH deficiency; discontinued 2008 (commercial, not safety) | Approved (Egrifta) for HIV-associated lipodystrophy |
| Visceral-fat evidence | No dedicated trial | ~15% reduction over 26 weeks (Phase III) |
| General profile | Gentler, closer to natural signaling | Stronger, more sustained stimulus |
| Monitoring | IGF-1 baseline + follow-up | IGF-1 baseline + follow-up |
| 2026 availability | Compounded, by prescription | Compounded / FDA-approved, by prescription |
Potency and half-life figures per comparative pharmacology sources; visceral-fat figures per tesamorelin Phase III trials. See Sources.
Which one fits whom?
Because the honest answer is “it depends,” here is how clinicians tend to frame the fit rather than the winner.
Sermorelin is often the first-line choice — the gentler, more physiologic entry point into the growth-hormone conversation, well-suited to someone supporting an age-related decline in the axis who wants to start measured and observe. Its shorter action keeps it closest to the body’s own pulsatile rhythm.
Tesamorelin is the more reasonable choice when the goal specifically points toward visceral fat and metabolic markers, where its evidence is strongest and its greater potency is doing real work. That extra potency is also why it asks for closer dosing attention.
Both apply to men and women alike. The growth-hormone axis declines with age in both sexes, so neither peptide is a men’s-only tool — a point worth making because the category’s marketing rarely does. And for both, the decision is anchored to bloodwork: a baseline that includes IGF-1 (the downstream marker of growth-hormone activity), and a follow-up to see whether the marker actually moves. That measurement is what turns a protocol into a decision rather than a hope — the same measure-first discipline behind why longevity medicine should start with your bloodwork.
What you can get in 2026
Both peptides are available today under prescription. Tesamorelin exists as an FDA-approved finished drug and as a compounded medication; sermorelin is available as a compounded medication prepared by state-licensed pharmacies. A compounded medication is not an FDA-approved finished product, and that distinction should always be visible to the patient. Growth-hormone secretagogues also work on a physiological timeline — most protocols need roughly three to six months before a fair read on the result. For the fuller picture on the gentler of the two, see what sermorelin is and who it fits.
How Trellis approaches the growth-hormone axis
Trellis Vitality is built as the accessibly-priced, patient-first alternative to premium-gated longevity clinics — the same clinical rigor, delivered on-demand and at home, without the five-figure annual membership. Growth-hormone-axis peptides are offered as flat monthly subscriptions inside that model, prescribed through a licensed clinical flow and dispensed by a compounding pharmacy where compounded.
Every new protocol begins with a free Vitality Lab Kit and a first protocol, so the choice between sermorelin and tesamorelin — and the choice to continue either — is anchored to your own IGF-1 and metabolic markers rather than to a testimonial. We do not run discount codes; the value is in the measurement and the supervision, not a countdown timer.
Sermorelin and tesamorelin are prescribed within a licensed clinical relationship. Compounded medications are not FDA-approved as finished products, and adult use for age-related restoration is off-label. Nothing here is a promise of results, and dosing is clinician-supervised.
Sermorelin vs tesamorelin FAQ
What’s the main difference between sermorelin and tesamorelin? Both prompt your own pituitary to release growth hormone, but tesamorelin is roughly 40× more potent, acts longer, and has visceral-fat trial data that sermorelin lacks. Sermorelin is gentler and closer to natural signaling.
Is tesamorelin stronger than sermorelin? Yes, substantially — about 40 times more potent, with a longer half-life. Stronger is a trade-off, not automatically better; it also warrants closer dosing attention.
Which is better for visceral fat? Tesamorelin, which reduced visceral fat by about 15% over 26 weeks in Phase III trials and is FDA-approved for that use in HIV-associated lipodystrophy. Sermorelin has no dedicated visceral-fat trial.
Is sermorelin better for beginners? It is often chosen first-line for its gentler, more physiologic profile, but the right starting point depends on your goal and baseline.
Are they FDA-approved? Tesamorelin is FDA-approved (Egrifta) for HIV-associated lipodystrophy. Sermorelin’s former branded form (Geref) was approved and later discontinued for business reasons; both are available today via prescription, sermorelin as a compounded medication.
Do both require monitoring? Yes. IGF-1 is the standard marker to check at baseline and follow-up for either peptide.
How long until results? Growth-hormone secretagogues typically need about three to six months before a fair assessment.
Can women use them? Yes. The growth-hormone axis declines with age in both men and women, and both peptides apply to both.
Can I switch between them? With clinician guidance, based on your response and goals — the two are not mutually exclusive over time.
The measured way to choose between them is to look at your own numbers first. Begin your assessment →
Sources
- Sermorelin vs Tesamorelin: clinical comparison (potency ~40×, half-life, structure). PlexusDx. https://plexusdx.com/blogs/learn/sermorelin-vs-tesamorelin
- FDA Approves EGRIFTA (tesamorelin) for reduction of excess abdominal fat in HIV-infected patients. FierceBiotech. https://www.fiercebiotech.com/biotech/fda-approves-egrifta%E2%84%A2-tesamorelin-for-injection-first-and-only-treatment-for-reduction-of
- Efficacy and Safety of Tesamorelin in People with HIV (visceral-fat reduction data). PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC11365754/
- Determination That GEREF (Sermorelin Acetate) Injection Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness. Federal Register, March 4, 2013. https://www.federalregister.gov/documents/2013/03/04/2013-04827/determination-that-geref-sermorelin-acetate-injection-05-milligrams-basevial-and-10-milligrams